Bronchonib 150mg Tablet

Bronchonib 150mg tablet is an anti-fibrotic medicine. It is used in the treatment to manage lung fibrosis which is caused by the disease of scleroderma and non small cell lung cancer. It contains an active ingredient of Nintedanib formulated as 150mg capsule. It works by inhibiting multiple tyrosine kinases involves in the formation of fibrosis, thereby slowing down the disease progression. The exact dose and duration is only recommended by the healthcare professional under strict medical conditions.

Treat lung fibrosis and non small cell lung cancer

Bronchonib 150mg tablet cause side effects. Some people experience mild and severe symptoms after using the medication. Visit the doctor if any of these symptoms persist:
● Diarrhea
● Nausea
● Vomiting
● Loss of appetite
● Abdominal pain
● High blood pressure
● Headache
● Breathlessness
● Weight loss
● Yellow eyes
● Bronchitis
● Bleeding problems
● Skin ulcer
● Hypertension
● fever

Bronchonib 150mg tablet should be taken with food, try to take it the fixed time time everyday. The medication should be taken based on response to the treatment, consume it with whole glass of water, do not crush or chew the tablet. Discuss with the doctor if you experience any of the side effects and if you have concerns about its use.

Scleroderma is an auto immune disease which causes excessive collagen build up, leading to skin thickening and potential damage to lung. Bronchonib 150mg tablet slow the progression of scarring (Fibrosis) in the lungs by reduces the activity of pathways that contribute to tissue damage and help to improve breathing and preserving lung function over time.

• Roth, G. J., Binder, R., Colbatzky, F., Dallinger, C., Schlenker-Herceg, R., Hilberg, F., ... & Kaiser, R. (2015). Nintedanib: from discovery to the clinic. Journal of medicinal chemistry, 58(3), 1053-1063.
• Richeldi, L., Du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., ... & Collard, H. R. (2014). Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. New England Journal of Medicine, 370(22), 2071-2082.
• Wollin, L., Wex, E., Pautsch, A., Schnapp, G., Hostettler, K. E., Stowasser, S., & Kolb, M. (2015). Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis. European Respiratory Journal, 45(5), 1434-1445.
• Rangarajan, S., Kurundkar, A., Kurundkar, D., Bernard, K., Sanders, Y. Y., Ding, Q., ... & Thannickal, V. J. (2016). Novel mechanisms for the antifibrotic action of nintedanib. American journal of respiratory cell and molecular biology, 54(1), 51-59.
• Wind, S., Schmid, U., Freiwald, M., Marzin, K., Lotz, R., Ebner, T., ... & Dallinger, C. (2019). Clinical pharmacokinetics and pharmacodynamics of nintedanib. Clinical pharmacokinetics, 58(9), 1131-1147.